- Home
- MDWD vs DHF Comparison
MDWD vs DHF Comparison
Compare MDWD & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- DHF
- Stock Information
- Founded
- MDWD 2000
- DHF 1998
- Country
- MDWD Israel
- DHF United States
- Employees
- MDWD N/A
- DHF N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- DHF Finance Companies
- Sector
- MDWD Health Care
- DHF Finance
- Exchange
- MDWD Nasdaq
- DHF Nasdaq
- Market Cap
- MDWD 184.8M
- DHF 188.4M
- IPO Year
- MDWD 2014
- DHF N/A
- Fundamental
- Price
- MDWD $18.29
- DHF $2.56
- Analyst Decision
- MDWD Strong Buy
- DHF
- Analyst Count
- MDWD 1
- DHF 0
- Target Price
- MDWD $25.00
- DHF N/A
- AVG Volume (30 Days)
- MDWD 59.3K
- DHF 451.1K
- Earning Date
- MDWD 11-26-2024
- DHF 01-01-0001
- Dividend Yield
- MDWD N/A
- DHF 7.65%
- EPS Growth
- MDWD N/A
- DHF N/A
- EPS
- MDWD N/A
- DHF N/A
- Revenue
- MDWD $19,720,000.00
- DHF N/A
- Revenue This Year
- MDWD $10.37
- DHF N/A
- Revenue Next Year
- MDWD $26.36
- DHF N/A
- P/E Ratio
- MDWD N/A
- DHF N/A
- Revenue Growth
- MDWD N/A
- DHF N/A
- 52 Week Low
- MDWD $11.04
- DHF $2.06
- 52 Week High
- MDWD $24.00
- DHF $2.39
- Technical
- Relative Strength Index (RSI)
- MDWD 57.26
- DHF 43.69
- Support Level
- MDWD $15.80
- DHF $2.53
- Resistance Level
- MDWD $18.25
- DHF $2.62
- Average True Range (ATR)
- MDWD 0.84
- DHF 0.03
- MACD
- MDWD -0.03
- DHF 0.00
- Stochastic Oscillator
- MDWD 95.77
- DHF 33.33
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.